atazanavir viatris
viatris limited - atazanavir sulfate 227.8mg equivalent to atazanavir 200mg; atazanavir sulfate 227.8mg equivalent to atazanavir 200mg - capsule - 200 mg - active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: brilliant blue fcf crospovidone erythrosine gelatin lactose monohydrate magnesium stearate purified water titanium dioxide active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: crospovidone gelatin indigo carmine iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water tekprint black sw-9008 titanium dioxide - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
apo-atazanavir atazanavir 200 mg (as sulfate) capsule blister pack
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: sodium starch glycollate type a; purified water; lactose monohydrate; magnesium stearate; hydrophobic colloidal silica anhydrous; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
apo-atazanavir atazanavir 200 mg (as sulfate) capsule bottle
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies
atazanavir apotex atazanavir 200 mg (as sulfate) capsule bottle
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: purified water; lactose monohydrate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies
atazanavir apotex atazanavir 200 mg (as sulfate) capsule blister pack
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies
atazanavir alphapharm atazanavir (as sulfate) 200 mg capsule bottle
alphapharm pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
atazanavir capsule, gelatin coated
greenstone llc - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - atazanavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: atazanavir is contraindicated: table 6 displays drugs that are contraindicated with atazanavir. drug class drugs within class that are contraindicated with atazanavir clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if atazanavir is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such
reyataz 200 mg
bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
atazanavir capsule, gelatin coated
cipla usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.[see use in specific populations (8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concen
reyataz- atazanavir capsule, gelatin coated
remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif